Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Common Equity (2016 - 2023)

Historic Common Equity for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to $14.7 million.

  • Aptevo Therapeutics' Common Equity fell 662.35% to $14.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $14.7 million, marking a year-over-year decrease of 662.35%. This contributed to the annual value of $18.0 million for FY2022, which is 137812.5% up from last year.
  • As of Q3 2023, Aptevo Therapeutics' Common Equity stood at $14.7 million, which was down 662.35% from $16.3 million recorded in Q2 2023.
  • In the past 5 years, Aptevo Therapeutics' Common Equity registered a high of $39.1 million during Q1 2019, and its lowest value of -$5.9 million during Q1 2022.
  • Over the past 5 years, Aptevo Therapeutics' median Common Equity value was $15.2 million (recorded in 2020), while the average stood at $14.6 million.
  • The largest annual percentage gain for Aptevo Therapeutics' Common Equity in the last 5 years was 137812.5% (2022), contrasted with its biggest fall of 15601.68% (2022).
  • Over the past 5 years, Aptevo Therapeutics' Common Equity (Quarter) stood at $11.8 million in 2019, then skyrocketed by 40.13% to $16.6 million in 2020, then tumbled by 92.67% to $1.2 million in 2021, then soared by 1378.12% to $18.0 million in 2022, then dropped by 18.12% to $14.7 million in 2023.
  • Its last three reported values are $14.7 million in Q3 2023, $16.3 million for Q2 2023, and $23.3 million during Q1 2023.